Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common ED drug help kids with heart failure?

NCT ID NCT07536880

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether sildenafil, a drug often used for erectile dysfunction, can improve heart function in children aged 1-18 with dilated cardiomyopathy, a condition where the heart is enlarged and weak. Researchers will measure changes in the heart's pumping ability over time. The trial aims to enroll 70 children and is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sildenafil
What this could lead to
If it works, sildenafil could become an add-on treatment to improve heart function in children with dilated cardiomyopathy.
What could go wrong
This is a small, early-stage study with only 70 children. It may not show significant benefit, and sildenafil can cause side effects like headache or flushing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children aged 1-18 years with a diagnosis of primary dilated cardiomyopathy confirmed by echocardiography, recruited from inpatient and outpatient pediatric cardiology services at Assiut University Children Hospital, Egypt.

Ages

1 year to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:- Children from 1-18 year's age, diagnosed primary dilated cardiomyopathy by echocardiography and are admitted at Pediatric Cardiology unit or attend Pediatric Cardiology outpatient clinic in Assiut University children hospital. * Patient on anti-failure therapy consistent with pediatric heart failure guidelines. Exclusion Criteria:. Patients less than 1 year old \- Patients with impaired left ventricular systolic function due to other causes like: i. Congenital heart diseases (anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA), severe coarctation of aorta, critical aortic stenosis, metabolic disorders as mitochondrial dysfunction or storage diseases. ii. Acquired heart diseases as myocarditis, Kawasaki, or arrhythmias * Post-Operative left ventricular dysfunction * Known hypersensitivity or contraindications to sildenafil as hypotension (\<90/50 mmHg), or severe hepatic/renal impairment or optic neuropathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiomyopathy, dilated are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiomyopathy, dilated

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.